A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia areata, which causes hair ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to ...

Oral ivarmacitinib, administered 4 mg or 8 mg once daily, significantly induced hair regrowth at 24 weeks vs. placebo in ...

Higher rates of venous thromboembolism, lymphoma, and infections were observed in those with atopic dermatitis and psoriasis vs control patients.

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198), emphasizing ...